MedTrace Logo

Italian Registry of Arthritis on Biologic Therapy

NCT01543594 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2020-09-29

No results posted yet for this study

Summary

The biologic drugs targeting TNFa, IL-6, IL-1, T cells, B cells have represented a fundamental discovery to treat rheumatic patients whose disease appears to be refractory to conventional therapy. These biologic drugs have been registered for human therapy from a few years, thereby the investigators miss long-term data for safety and efficacy. Aim of this study is to register all the clinical data of patients with rheumatoid arthritis and spondyloarthritis beginning a treatment with biologic drugs in order to assess the long-term safety and efficacy in the real life.

Conditions

Sponsors & Collaborators

  • Gruppo Italiano Studio Early Arthritis

    lead NETWORK

Principal Investigators

  • Florenzo Iannone, MD · University of Bari

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2022-05-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543594 on ClinicalTrials.gov